a patch with nanoparticles... , page-5

PeterN23,
Im currently for business in Taiwan and on my way to India. Therefore I have not researched this topic to the degree I would have liked, but certainly will in future.

here my opinion as far as I have reached it:

POHs chemical TPM approach or OBJs electromagnetic approach combining electroporation and iontophoresis seems to me years ahead of nanotechnology.
According to the researchers themselves, the nanopatch is at least 5 years from reaching market applications (which would be amazingly fast).

I have invested already years ago in the US in nanotechnology companies with a loss as their maturing cycle and market availability is often only to be seen long term.
I have no doubt that nanotechnology will have far reaching applications, especially in materials, like adding nano particles to materials like traditional polymer and reducing weight and increasing flexibility vastly.
The nanopatch itself is extremely interesting and will help to reduce costs, availability of vaccines.


The nanopatch targets the stratum granulosum, one of the layers of the epidermis situated just under to the stratum corneum, except in the palms of the hands and the soles of the feet, where it lies just under the stratum lucidum.

The cells in the stratum granulosum, or granular layer, have lost their nuclei and are characterized by dark clumps of cytoplasmic material, these disintegrated cell parts contain viral structures. There is a lot of activity in this layer as keratin proteins and water-proofing lipids are being produced and organized.
This area of the epidermis contains antigens, as for example lichen planus specific antigen (LPSA), present only in the stratum granulosum and stratum spinosum and absent from other parts of the epidermis.
Since the nanopatch targets these areas directly instead of muscle tissue, the vaccines are far more effective in the immune cell rich stratum granulosum.


Our OBJ patch targets the dermal barrier of the stratum corneum with electroporation to enter the blood stream in this fashion.
Therefore the nanopatch and the OBJ em-patch are targeting different areas of the skin and have entirely different applications.
The nanopatch targets the stratum granulosum to access the immune system and is therefore restricted to vaccines.

The OBJ patch is a technology to allow drugs, peptides and larger molecules to pass through the dermal barrier and being transported by inotophoresis through the skin to reach the blood stream.
Its therapeutic applications, in my opinion, always was most interesting in pain and anti-inflammatory medications for long term prescriptions.
Our OBJ patch has also vast applications in dental, hair and cosmetic areas.


If anything, these news of the outlook of nanopatches enrich the transdermal delivery market and can only be good news for OBJ holders as this industry shows plenty of signs of maturing and creating market interest.